Primary Mediastinal B-Cell Lymphoma – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Primary Mediastinal B-Cell Lymphoma – Drugs In Development, 2023’, provides an overview of the Primary Mediastinal B-Cell Lymphoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Primary Mediastinal B-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Mediastinal B-Cell Lymphoma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Primary Mediastinal B-Cell Lymphoma
- The report reviews pipeline therapeutics for Primary Mediastinal B-Cell Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Primary Mediastinal B-Cell Lymphoma therapeutics and enlists all their major and minor projects
- The report assesses Primary Mediastinal B-Cell Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Primary Mediastinal B-Cell Lymphoma
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Primary Mediastinal B-Cell Lymphoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Primary Mediastinal B-Cell Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
2Seventy Bio IncAbbVie Inc
AbelZeta Inc
Agenus Inc
Allogene Therapeutics Inc
ALX Oncology Holdings Inc
AstraZeneca Plc
Aurigene Oncology Ltd
Autolus Therapeutics Plc
AVM Biotechnology LLC
Bambino Gesu Hospital and Research Institute
BeiGene Ltd
Beijing Boren Hospital
Beijing Immunochina Pharmaceuticals Co Ltd
Bellicum Pharmaceuticals Inc
Bristar Immunotech Biotechnology Co Ltd
Bristol-Myers Squibb Co
BRL Medicine Inc
California Institute for Biomedical Research
CARGO Therapeutics Inc
Caribou Biosciences Inc
Cellectis SA
Century Therapeutics Inc
CHO Pharma Inc
Chongqing Precision Biotech Co Ltd
CoImmune Inc
Cullinan Oncology Inc
Curocell Inc
Daiichi Sankyo Co Ltd
Excelmab Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Genentech USA Inc
General Hospital of the People's Liberation Army
Genmab AS
Genor BioPharma Co Ltd
Gilead Sciences Inc
Gracell Biotechnologies Inc
Guangdong Second Provincial General Hospital
Hangzhou Rongu Biotechnology Co Ltd
Hebei Senlang Biotechnology Co Ltd
HRAIN Biotechnology Co Ltd
Huadao Shanghai Biomedical Co Ltd
Huazhong University of Science & Technology
Hutchmed China Ltd
I-Mab
ImmPACT Bio USA Inc
ImmunoAct Pvt Ltd
Immunotech Biopharm Ltd
Imugene Ltd
Innovative Cellular Therapeutics Co Ltd
Ipsen SA
Janssen Biotech Inc
JSR Life Sciences LLC
Juventas Cell Therapy Ltd
JW Cayman Therapeutics Co Ltd
Karyopharm Therapeutics Inc
Kesios Therapeutics Ltd
KK Women's and Children's Hospital
Leman Biotech Co Ltd
Marino Biotechnology Co Ltd
Massachusetts General Hospital
Medical College of Wisconsin
Merck & Co Inc
Miltenyi Biomedicine GmbH
Mustang Bio Inc
Nanjing Bioheng Biotech Co Ltd
Nanjing IASO Biotherapeutics Co Ltd
National Cancer Institute US
Nektar Therapeutics
Novartis AG
Oncternal Therapeutics
Ottawa Hospital Research Institute
Pell Bio-Med Technology Co Ltd
PeproMene Bio Inc
Pfizer Inc
Prelude Therapeutics Inc
Priothera Ltd
QLSF Biotherapeutics Inc
Regeneron Pharmaceuticals Inc
Sana Biotechnology Inc
Seagen Inc
Shanghai Cell Therapy Group Co
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Shanghai YaKe Biotechnology Co Ltd
Shengke Pharmaceuticals (Jiangsu) Ltd
Shenzhen Geno-Immune Medical Institute
Sunnycell Therapeutics Ltd
Suzhou Fundamenta Therapeutics Co Ltd
Tachyon Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Tessa Therapeutics Ltd
Tongji University School of Medicine
University of Colorado Denver
University of Texas MD Anderson Cancer Center
UWELL Biopharma Inc
Vincerx Pharma Inc
Wellington Zhaotai Therapies Ltd
West Lake Biomedical Technology (Hangzhou) Co Ltd
Wuhan Bio-Raid Biotechnology Co Ltd
Wyze Biotech Co Ltd
Yikesite (Beijing) Pharmaceutical Technology Development Co Ltd
Zhejiang Borui Biopharmaceutical Co Ltd
Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang University
Zhejiang University School of Medicine Hospital 1
Zhejiang University School of Medicine Hospital 2